The immune response to HIV-1 Virus-Like Particles (VLPs), presenting a clade A Ugandan gp120, has been evaluated in a mouse model by intranasal (i.n.) administration by a VLP+VLP homologous or a DNA+VLP heterologous prime-boost immunization protocol, including a HIV-1 DNA gp160/rev plasmid. Furthermore, the effect of the Eurocine lipidbased mucosal L3 adjuvant on the VLP immunogenicity has been assessed as well.
INTRODUCTION
Virus-like particles (VLPs) represent an antigen presenting and delivery system currently under investigation as potential vaccine for different human viruses, such as Hepatitis, Papilloma, Rotavirus, Parvovirus and Norwalk virus [1] [2] [3] [4] [5] [6] . The HIV-targeted VLPs (HIVVLPs) are based on the HIV-1 Pr55gag precursor protein property to assemble as immature, non-replicating and non-infectious VLPs with an effective induction of both arms of the immune response [7] [8] [9] [10] [11] [12] [13] . In particular, the enveloped HIV-VLPs developed in our laboratory present an entire gp120 molecule derived from an Ugandan HIV-1 isolate of the clade A, identified in our laboratory [11;14;15] . The HIV-VLP A s show a strong in vivo immunogenicity in Balb/c mice, in absence of adjuvants, and HIV-1-specific CTLs as well as cross-clade neutralizing antibodies, active on primary HIV-1 isolates, have been detected in immunized animals [12] . Furthermore, the immunogenicity of the HIV-VLP A s has been evaluated in Balb/c mice by intra-nasal (i.n.) routes, in a homologous (VLP+VLP) primeboost protocol without any adjuvant formulation, showing the induction of humoral IgA and/or IgG antibody response with neutralizing activity, in sera and at mucosal (vaginal and intestinal) sites, as well as cellular immune response [16] .
Heterologous prime-boost vaccination strategies have been originally developed to improve the CD8+ T cell response, combining a DNA or VLP priming with live-vector boosters. This was based on the rationale that the DNA or VLPs are able to drive epitopes into the MHC class I pathway and to make the immune response focused only on the desired vaccine antigen, while the live-vector booster enhances this immune response by both expressing large amounts of antigen and stimulating a pro-inflammatory response [17;18] . However, several observations indicate that, although cell-mediated immunity is crucial for controlling and eradicating viral infections, neutralizing antibodies are pivotal in reducing the infectivity titer of the initial HIV-1 inoculum (potentially to sterilization) as well as neutralizing free virions during the first rounds of replication. This greatly facilitates the outcome of the second line of defense operated by effector T cells that are required to eliminate virus-infected cells [19] [20] [21] [22] . Consequently, anti-HIV-1 prime-boost vaccination strategies should include a protein component to induce an optimal titer of neutralizing antibodies [23;24] . In this context, a VLP boosting would represent an extremely appropriate choice, given the several advantages over the single recombinant protein vaccines. In particular, 1) to present envelope antigens in their native form; 2) to enter into professional antigen-presenting cells (APCs) by either phagocytosis or receptormediated uptake; 3) to activate the endogenous as well as exogenous pathways leading to the presentation of viral antigens by both MHC class I and class II molecules [13;25] . This results in induction of both arms of immune response and, specifically, effective neutralizing antibodies directed against conformational epitopes. A strategy based on DNA priming and VLP boosting has been previously shown to elicit a strong systemic neutralizing humoral response when administered intramuscularly [26] or intradermally [27] .
Considering that the transmission of HIV-1 infection during heterosexual or homosexual intercourse accounts for as much as 80% of AIDS globally, a specific mucosal immunity is extremely relevant for controlling the primary HIV-1 transmission. This can be achieved by mucosally delivered vaccines which, besides the advantage of conferring mucosal as well as systemic immunity, show an increased stability and allow the elimination of needles. This, especially in developing countries, may significantly reduce the risk of further spreading HIV-1 infection. Moreover, the immunogenic efficacy of mucosal vaccines would greatly benefit from the co-administration with mucosal adjuvants that can initiate and support the transition from innate to adaptive immunity.
In this respect, the Eurocine L3 is a potent mucosal adjuvant for protein vaccines [28] , based on mono-olein/oleic acid vesicles approved for human use as a nasal vaccine adjuvant and already employed in a phase I clinical trial, performed in Sweden, for nasal immunization with diphtheria vaccine. Moreover, it has been evaluated in intra-nasal immunization protocol with heat-killed Mycobacterium bovis bacilli Calmette-Guerin (BCG), inducing levels of protection comparable to the conventional live BCG vaccine [29] .
In the present study, the mucosal immunogenicity of HIV-VLP A s has been evaluated in a homologous (VLP+VLP) and heterologous (DNA+VLP) prime-boost strategy by intra-nasal administration. In order to achieve a broader neutralizing activity, a multi-clade approach has been designed employing envelope molecules of B (DNA) and A (VLP) subtypes.
Furthermore, the enhancing effect of the L3 adjuvant on the HIV-VLP A s immunogenicity has been assessed as well.
MATERIALS AND METHODS

Immunization experiments.
Female Balb/c mice, each group consisting of six animals 6-8 weeks of age, were intranasally immunized with 8 g HIV-1 gp160/rev DNA mixed with 2% N3 adjuvant [30] or with 2 g rVLPgag/gp160 clade A mixed with PBS or 2% L3-adjuvant. After 4 weeks, mice were intranasally boostered with 2 ug rVLPgag/gp120 clade A mixed with PBS or 2% L3-adjuvant. For both primary and booster immunizations, mice were anastezised for 2 min with Isofurane gas and immunogen (6-7 l/nose nare) was given in the nose at a total volume of 14 l/mouse. The mice were awake approx. 1 min after receiving the immunogen.
Sample collection and processing.
All samples to be tested were collected at 3 weeks post each immunization. IgA and presumably also IgG from the vaginal mucus, samples were thawed, weighed, and extracted twice for 2 hr each time in 100 l of PBS per sample, with rotation at 20 rpm in a 12-ml polystyrene tube at 4°C. The two extracts and the original wash supernatant were pooled, made up to 300 l per sample, and frozen at -80°C until needed [16;31] .
Intestinal washes. Fecal pellets were resuspended at a 10% (wt/vol) concentration in a stool diluent (10 mM Tris pH 7.5, 100 mM NaCl, 1 mM CaCl2 , 0.05% Tween 20, 5 mM sodium azide, additioned with 1 mg of aprotinin/ml and 10 mg of leupeptin/ml). After incubation on ice for 20min, suspensions were centrifuged at 18,000 x g for 15min in order to remove fecal solids. Processed fecal antibody samples were stored at -80°C [16;32] .
Serological Assays.
Nunclon 96 well ELISA plates were coated with 1 g/ml recombinant gp160 (BioSciences, CT) or rp24 antigen (Aalto, Dublin) 0,5 g/ml (both antigens of the B-clade). Serum dilutions 1/100-1/100 000 (PBS-0,5%BSA-0,1% Tween20) were incubated for 2h at 37°C. 
B cell epitope mapping.
The anti-envelope serum IgG response was mapped by pooled sera using 48 individual peptides (15-mers with 5-mer overlap) representing amino acids 249-514 of gp120 HIV-1 subtype B [33;34] . The serum was diluted in 10-fold serial dilutions (starting with dilution 1/100) and reactive antibodies were detected with goat anti-mouse IgG antibodies conjugated to horseradish peroxidase (HRP) (Bio-Rad, CA, USA). Plates were developed with O-phenylenediamine and the OD was read at 490nm.
HIV-1 neutralization assay.
Serum from preimmunized and immunized mice were heat-inactivated (56°C for 30 200 l of fresh medium was added to each well. Every 3 days, 100 l of medium was changed. After 6-7 days, 100 l of supernatant from each well was collected, and virus production was measured in a p24 Ag capture ELISA as previously described [35] .
Cell mediated immunity.
Lymphocyte proliferation and cytokine production. The lymphocyte proliferation was performed essentially as described earlier [36] . Single-cell suspensions were prepared from spleen and lymph nodes and 4x10 5 cells/per well were co-cultured with antigen (0.1 mg rgp160 or rgagp24 or medium, ProteinSciences, CT per well) for 3 days before tritium-H3-labeled thymidine (1uCi/ml) was added to each well and incubated for 16h. The cells were harvested and counted in a -counter (Wallac1450, Finland). After 72h, interferon- was determined in the culture supernatants by ELISA in accordance with the manufacturer's instructions (R&DSystems, UK).
Statistical analyses.
Intergroup comparisons were performed with the unpaired two-sided Student's t-test. All P values were two-tailed and considered significant if less than 0.05.
RESULTS
Induction of serum antibody response by intra-nasal administration.
HIV-VLP A s, produced in insect cells and purified on a 10-60% continuous sucrose gradient [11] , were administered intra-nasally in Balb/c mice following a prime-boost protocol defined "homologous" (VLP prime + VLP boost) or "heterologous" (DNA prime + VLP boost) boosting, with or without the L3 adjuvant (Table 1) . Moreover, to achieve a broader neutralizing activity, the heterologous protocol can be considered also a multiclade approach, given that the DNA plasmid expresses a B-clade and the VLP an A-clade envelope.
Animals were boosted 4 weeks after the priming immunization and serum was collected by tail vein bleeding three weeks after the single boosting dose. Each immunization group contained 6 animals which did not show signs of toxicity and remained healthy up to the end of the vaccination protocol.
ELISA tests were performed on microwell plates coated with recombinant gp160 or p24. The data show that the heterologous prime-boost protocol induces a statistically significant increase of serum anti-env IgG and IgA titers, compared to the homologous protocol. Only the IgA titers are further increased in the heterologous protocol when the single VLP boost is adjuvanted in L3 ( Fig. 1A and C) . The serum anti-gag IgG and IgA titers, instead, are low and equivalent in both homologous and heterologous nonadjuvanted protocols, resulting considerably increased (1 -2 logs) in both protocols when the single VLP boost is adjuvanted in L3 (Fig. 1B and D) .
Induction of mucosal antibody response by intra-nasal administration.
In order to quantify the antibody response at mucosal level, vaginal and intestinal washes were collected from each animal three weeks after the single VLP boosting dose and evaluated in the ELISA system. The results show that, also at vaginal as well as intestinal level, the heterologous prime-boost protocol induces a statistically significant increase of anti-env IgG and IgA titers, compared to the homologous protocol. Only the intestinal IgA titers are further increased in the homologous protocol when the single VLP boost is adjuvanted in L3 ( Fig. 2A and C) . The mucosal anti-gag IgA titers are low and equivalent in both homologous and heterologous non-adjuvanted protocols, resulting significantly increased in both protocols when the single VLP boost is adjuvanted ( Fig. 2B and D) . The magnitude of this increase is particularly relevant at vaginal level, calculated as a 26.6-fold increase of the geometric mean titer in the homologous protocol and 47.9-fold increase in the heterologous protocol.
The results obtained at systemic and mucosal levels with these prime-boost protocols, performed with a single VLP boosting dose of 2ug, are particularly interesting compared to our previous results obtained with 4 doses of VLP (20 and 100 ug/dose) without adjuvant [16] . In particular, the vaginal IgA anti-gag response is considerably increased in both homologous and heterologous protocols adjuvanted in L3 (8.06 folds the homologous and 14.38 folds the heterologous) ( Table 2) . At intestinal level, the homologous protocol does not improve the previously observed response, while the heterologous protocol induces a 2-3-fold increase of IgA titer compared to previous immunization schedules as well as the homologous protocol ( Table 2 ). 
Evaluation of B-cell epitopes recognized by immune sera.
Serum from immunized animals were evaluated for mapping their recognition of B cell epitopes in the gp120 C2 -V5 region, using overlapping linear peptides as target. Serum from animals immunized with either the homologous or the heterologous prime-boost protocol showed a wide-spread recognition pattern along the considered region (Fig. 3) . In particular, the DNA+VLP heterologous protocol mostly induced an increased binding to individual epitopes covering the C2-V3 region, compared to the VLP-VLP homologous protocol, and did not present additional "masked" epitopes to the immune system. On the contrary, the two protocols induced either the same level of recognition or very limited response against other epitopes (Fig. 3) . Overall, the strongest binding was observed against the V3 and V4 peptides, outside the gp120 regions identified as involved in the CD4 binding [37] .
Ex vivo neutralization activity of immune sera.
Neutralization activity of antibodies induced by the single HIV-VLP A s boost in mice immunized with either the homologous or the heterologous prime-boost protocol, was verified ex vivo against heterologous A-and B-clade isolates. The results showed that immune sera derived from mice immunized with both non-adjuvanted protocols, did not show a significant neutralization activity against the virus isolates (data not shown). On the contrary, when the single VLP boosting dose was administered in the L3 adjuvant, the immune sera induced by the homologous protocol show a >50% neutralization activity at a 1:20 final dilution against both A and B heterologous isolates, when used at a MOI of 30 and 40, respectively (Fig. 4 A and C) . The neutralization activity was not as efficient when the heterologous isolates were used at a double MOI (Fig. 4 B and D) . The immune sera induced by the heterologous protocol, instead, showed a >50% neutralization activity up to a 1:60 final dilution against the heterologous B-clade isolate, at either MOI (Fig. 4 E and F) .
A >50% neutralization activity was observed at a 1:20 final dilution against the heterologous primary A-clade isolate, only when used at a 30 MOI (Fig. 4 G and H) .
The pre-immune sera from immunized mice did not show any neutralization activity and both viral isolates showed a similar effective kinetic of replication in the 7-day p.i.
experiment, characterized by a progressive increase of virus production, measured as p24 concentration (data not shown).
Cellular response in HIV-VLP A s-immunized animals.
To assess the induction of Env-and Gag-specific cellular response, spleens and lymph nodes were removed from immunized mice and the IFN production was evaluated in cell culture after ex vivo restimulation with either Env or Gag peptides. The results showed that the heterologous prime-boost protocol induces a statistically significant increase of increased IFN production specific for the Env epitopes in the spleen and lymph nodes, compared to the homologous protocol. This is not further increased in the both protocols when the single VLP boost is adjuvanted in L3 (Fig. 5A and C) . The IFN production specific for the Gag epitopes in the spleen and lymph nodes, instead, are low and equivalent in both homologous and heterologous non-adjuvanted protocols, resulting considerably increased in both protocols when the single VLP boost is adjuvanted in L3
( Fig. 5B and D) . In particular, the levels of anti-gag IFN production were significantly higher in the lymph node than in the spleen (p <0.0001).
Similar results were observed evaluating the proliferation of T helper cells from immunized mice when ex vivo restimulated with either Env or Gag peptides. Again, the heterologous prime-boost protocol induces a statistically significant increase of T helper proliferation (expressed as Stimulation Index -S.I.) specific for the Env epitopes, compared to the homologous protocol. This is not further increased in the both protocols when the single VLP boost is adjuvanted in L3 (Fig. 6A) . The T helper proliferation specific for the Gag epitopes, instead, are low and equivalent in both homologous and heterologous non-adjuvanted protocols, resulting statistically increased in both protocols when the single VLP boost is adjuvanted in L3 (Fig. 6B ). 
DISCUSSION
We have previously reported that a candidate HIV-1 preventive vaccine, based on VLPs expressing a gp120 glycoprotein derived from an HIV-1 clade A isolate (HIV-VLP A s) [11] , induces IgA and/or IgG antibody responses in sera as well as at mucosal (vaginal and intestinal) sites and CTL activity when administered by multi-regimen protocol in BALB/c mice by the intra-nasal route in the absence of adjuvants [12;16] . These results were obtained using 20 and 100 g/dose.
In the present study, the HIV-VLP A s immunogenicity has been evaluated in a Balb/c mouse model by intra-nasal administration, comparing a VLP+VLP homologous vs a DNA+VLP heterologous prime-boost immunization protocol and evaluating the enhancing effect of the Eurocine L3 mucosal adjuvant. In this case, the single VLP boosting dose was 2 g.
The results showed that the non-adjuvanted heterologous protocol induced a statistically significant increase of serum anti-env Ig titers, compared to the homologous protocol, and that the single adjuvanted HIV-VLP A boost, either in the homologous or in the heterologous protocol, induced a relevant increase of the serum anti-gag response. This effect was less dramatic for the anti-env response but a statistically significant increase of serum IgA was observed in the heterologous protocol ( Fig. 1 A-D) . Similar results were observed at mucosal (vaginal and intestinal) sites (Fig. 2 A-D) .
The B-cell epitope mapping analysis showed that the homologous and the heterologous prime-boost protocols are comparable in presenting gp120 epitopes to the immune system, given that no epitope appears to be exposed only in one of the two protocols (Fig. 3) . The Furthermore, the non-adjuvanted heterologous protocol induced a statistically significant increase of IFN production ( Fig. 5 A and C) and T helper proliferation (Fig. 6 A) specific for env epitopes, compared to the homologous protocol, not further increased in the both protocols when the single VLP boost is adjuvanted. The single adjuvanted HIV-VLP A boost, either in the homologous or in the heterologous protocol, induced an increased IFN production ( Fig. 5 B and D) and T helper proliferation (Fig. 6 B) specific for gag epitopes, compared to the protocols including a non-adjuvanted VLP.
These data confirm the efficient induction of humoral and cellular systemic as well as mucosal immunity by intra-nasal administration of HIV-VLP A s, as previously reported [16] . This is likely due to efficient presentation in the major histocompatibility complex (MHC)
class I and II context with a resulting activation of both Th1 and Th2 pathways, as recently shown in studies on VLP-activated dendritic cells [38;39] .
The designed heterologous protocol, based on a DNA prime and a single VLP boosting dose, is able to increase the env-specific humoral and cellular immune response, which is to some extent increased by the administration of adjuvanted VLP boost. On the contrary, the L3 adjuvant appears to be extremely efficient in increasing the anti-gag response in both homologous and heterologous protocol.
These results are obtained with a 1/10 of the previously used HIV-VLP A s dose (2 vs 20 g), inducing significantly higher geometric mean titers of systemic and mucosal antibodies, with cross-clade neutralizing activity, compared to our previous studies performed with multiple doses of non-adjuvanted VLPs [12;16] . This strongly indicates that the prime boost protocols and, in particular, the adjuvant effect of the L3 is extremely efficient in stimulating the mucosa-associated lymphoid tissue, possibly initiating and supporting the transition from innate to adaptive immunity. The results confirm previous observations reported for the heat-killed bacille Calmette-Guerin (BCG) model which, formulated in the L3 adjuvant, induces immune response and immune protection comparable to the conventional live BCG vaccine [29] .
The more efficient induction of anti-gag than ant-env response with a single VLP boost, either in the homologous or in the heterologous protocol, strongly suggests that the Gag:Env ratio in the HIV-VLP A s is in great favor of Gag, as described for the native HIV-1 particles (40 to 60:1, Gag:Env) [40;41] . This implies that the antigen load carried by the HIV-VLP A s is significantly higher for gag than for env and, consequently, the single HIV-VLP A dose is more efficient in boosting the anti-gag response. Moreover, this observation could also result from the generally reported lower immunogenicity of env compared to gag protein, as consequence of high degree of protein glycosylation [42;43] . To ensure an optimal env antigen presentation, immunization protocols designed with multiple HIV-VLP A boosting doses are under evaluation.
In particular, the relevant anti-gag humoral response, not expected to be involved in GMT obtained by ELISA performed using whole VLPs as target antigen; § Single VLP boosting dose of 2ug. GMT obtained by ELISA performed using whole individual env or gag proteins as target antigen.
